Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-03-2012 | Short Communication

Differential expression of HINT1 in schizophrenia brain tissue

Authors: Jeeva Varadarajulu, Andrea Schmitt, Peter Falkai, Murtada Alsaif, Christoph W. Turck, Daniel Martins-de-Souza

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 2/2012

Abstract

Recent findings in the literature suggest a relation between histidine triad nucleotide-binding protein-1 (HINT1) and psychiatric disorders such as major depression, anxiety, and schizophrenia, although its physiological roles are not completely comprehended. Using Western blot, we compared HINT1 protein expression in the postmortem dorsolateral prefrontal cortex and thalamus of schizophrenia patients and healthy controls for contributing to elucidate the role of HINT1 in schizophrenia pathophysiology. HINT1 was found to be downregulated in the dorsolateral prefrontal cortex and upregulated in the thalamus. Our results combined to previous studies in human samples and preclinical models support the notion that HINT1 must be more explored as a potential target for psychiatric disorders.

Brzoska PM, Chen H, Levin NA, Kuo WL, Collins C, Fu KK, Gray JW, Christman MF (1996) Cloning, mapping, and in vivo localization of a human member of the PKCI-1 protein family (PRKCNH1). Genomics 36(1):151–156PubMedCrossRef

Su T, Suzui M, Wang L, Lin CS, Xing WQ, Weinstein IB (2003) Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci USA 100(13):7824–7829PubMedCrossRef

Barbier E, Zapata A, Oh E, Liu Q, Zhu F, Undie A, Shippenberg T, Wang JB (2007) Supersensitivity to amphetamine in protein kinase-C interacting protein/HINT1 knockout mice. Neuropsychopharmacology 32(8):1774–1782PubMedCrossRef

Barbier E, Wang JB (2009) Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level. BMC Neurosci 10:132PubMedCrossRef

Varadarajulu J, Lebar M, Krishnamoorthy G, Habelt S, Lu J, Bernard Weinstein I, Li H, Holsboer F, Turck CW, Touma C (2011) Increased anxiety-related behaviour in Hint1 knockout mice. Behav Brain Res. [Epub ahead of print]

Liu Q, Puche AC, Wang JB (2008) Distribution and expression of protein kinase C interactive protein (PKCI/HINT1) in mouse central nervous system (CNS). Neurochem Res 33(7):1263–1276PubMedCrossRef

Weitzdoerfer R, Stolzlechner D, Dierssen M, Ferreres J, Fountoulakis M, Lubec G (2001) Reduction of nucleoside diphosphate kinase B, Rab GDP-dissociation inhibitor beta and histidine triad nucleotide-binding protein in fetal Down syndrome brain. J Neural Transm Suppl 61:347–359PubMed

Chen Q, Wang X, O’Neill FA, Walsh D, Kendler KS, Chen X (2008) Is the histidine triad nucleotide-binding protein (HINT1) gene a candidate for schizophrenia? Schizophr Res 106:200–207PubMedCrossRef

Jackson KJ, Chen Q, Chen J, Aggen SH, Kendler KS, Chen X (2011) Association of the histidine-triad nucleotide-binding protein-1 (HINT1) gene variants with nicotine dependence. Pharmacogenomics J. [Epub ahead of print]

10.

Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, Freed WJ (2002) Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: a preliminary study. Schizophr Res 58:11–20PubMedCrossRef

11.

Steriade M, Llinás RR (1988) The functional states of the thalamus and the associated neuronal interplay. Physiol Rev 68(3):649–742

12.

Andreasen NC, Arndtm S, Swayze V 2nd, Cizadlo T, Flaum M, O’Leary D, Ehrhardt JC, Yuh WT (1994) Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266:294–298PubMedCrossRef

13.

Barch DM (2005) The cognitive neuroscience of schizophrenia. Annu Rev Clin Psychol 1:321–353PubMedCrossRef

14.

American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington

15.

Jahn T, Mussgay L (1989) Die statistische Kontrolle möglicher Medikamenteneinflüsse in experimentalpsychologischen Schizophreniestudien: Ein Vorschlag zur Berechnung von Chlorpromazinäquivalenten. Zeitschrift für klinische Psychologie und Psychotherapie 18:257e67

16.

Meltzer HY, Fatemi SH (1998) Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB (eds) The American psychiatric text book of psychopharmacology. American Psychiatric Press, Washington, pp 127–135

17.

Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112(4):389–404PubMedCrossRef

18.

Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239–259PubMedCrossRef

19.

Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, Turck CW (2009) Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259(3):151–163PubMedCrossRef

20.

Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, Falkai P, Schmitt A, Turck CW (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatr Res 44(16):1176–1189PubMedCrossRef

21.

Martins-de-Souza D, Menezes de Oliveira B, dos Santos Farias A, Horiuchi RS, Crepaldi Domingues C, de Paula E, Marangoni S, Gattaz WF, Dias-Neto E, Camillo Novello J (2007) The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. Brief Funct Genomic Proteomic 6(1):70–75PubMedCrossRef

22.

Martins-de-Souza D (2010) Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260(7):561–562PubMedCrossRef

Title: Differential expression of HINT1 in schizophrenia brain tissue
Authors: Jeeva Varadarajulu
Andrea Schmitt
Peter Falkai
Murtada Alsaif
Christoph W. Turck
Daniel Martins-de-Souza
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 2/2012
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-011-0216-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Differential expression of HINT1 in schizophrenia brain tissue

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Dissociable and common deficits in inhibitory control in schizophrenia and bipolar disorder

Critical trial-related criteria in acute schizophrenia studies

Neurobiology of schizophrenia: from outcome to pathophysiological insights

Is symptomatic treatment an option for a boy with clinically significant psychotic-like experiences and depressed mood? Comment on Ruhrmann et al., “intervention in at-risk states for developing psychosis.” (Eur Arch Psychiatry Clin Neurosci 260 Suppl 2:S90–94)

Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders

General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia